Coeptis Therapeutics is focused on developing innovative cell therapy platforms aimed at improving outcomes for cancer patients. One of their key technologies is the GEAR-NK (CD38) platform, which leverages modified Natural Killer (NK) cells to enhance the efficacy of existing anti-CD38 monoclonal antibody therapies. The GEAR-NK technology is designed to protect CD38+ NK cells from being targeted and destroyed by these therapies, thereby preserving their ability to recognize and eliminate cancer cells. This approach aims to create a synergistic effect, allowing for more effective tumor killing while maintaining immune surveillance.

In addition to the GEAR-NK platform, Coeptis is also developing a CD38-based in vitro diagnostic tool. This diagnostic aims to identify cancer patients who are most likely to benefit from targeted monoclonal antibody therapies, either alone or in combination with GEAR-NK treatments. By enhancing patient selection, this diagnostic tool seeks to optimize therapeutic outcomes and reduce unnecessary exposure to less effective treatments, aligning with global healthcare priorities for cost-effective and predictable cancer care solutions.

United States

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.

COEPTIS

Company Details